NCT01192243

Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients

Phase 2 Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 68 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to examine the efficacy and safety of gefitinib combinated with Pemetrexed/Cisplatin in advanced non-small cell lung cancer (NSCLC).

Conditions

• Toxicity
• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Gefitinib	250mg qd po d3-16
DRUG	Pemetrexed	500mg/m2 venous infusion,D1,q3w
DRUG	Cisplatin or carboplatin	Cisplatin:75mg/m2, venous infusion,D1,q3w or Carboplatin: AUC 5, venous infusion, D1,q3w

Timeline

• Start date: 2009-12-01
• Primary completion: 2011-12-01
• First posted: 2010-09-01
• Last updated: 2010-09-03

Locations

1 site across 1 country: China